Gifre, L <br/><br/>
Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  Jan 2016 
 - 405-10 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1433-2965 
<br/><br/><label>Standard No.: </label>10.1007/s00198-015-3333-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Biomarkers--blood<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--therapeutic use<br/>Bone Remodeling--drug effects<br/>Denosumab--therapeutic use<br/>Female<br/>Femur Neck--drug effects<br/>Follow-Up Studies<br/>Hip Joint--drug effects<br/>Humans<br/>Lumbar Vertebrae--drug effects<br/>Male<br/>Middle Aged<br/>Osteoporosis--drug therapy<br/>Spinal Cord Injuries--complications<br/>Young Adult